Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 8
2005 8
2006 6
2007 9
2008 6
2009 8
2010 8
2011 9
2012 8
2013 4
2014 4
2015 4
2016 10
2017 9
2018 2
2019 6
2020 9
2021 5
2022 5
2023 5
2024 6
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Defining breast epithelial cell types in the single-cell era.
Gray GK, Carlson EG, Lev T, Marshall B, Reed AD, Sánchez-Covarrubias AP, Twigger AJ, Puig-Barbe A, Thennavan A, Omotoso A, Murrow LM, Chatterjee D, He S, Pensa S, Aevermann B, Tavares NK, Chen N, Hilton JA, Blake K, Liu Y, Phong K, Gartner ZJ, Lawson DA, Swarbrick A, Dos Santos CO, George SHL, Brugge JS, LaBarge MA, Nakshatri H, Navin N, Kessenbrock K, Khaled WT. Gray GK, et al. Among authors: brugge js. Dev Cell. 2025 Sep 8;60(17):2218-2236. doi: 10.1016/j.devcel.2025.06.032. Dev Cell. 2025. PMID: 40925326 Free article. Review.
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
Stover EH, Lee EK, Shapiro GI, Brugge JS, Matulonis UA, Liu JF. Stover EH, et al. Among authors: brugge js. Gynecol Oncol. 2025 Sep;200:22-32. doi: 10.1016/j.ygyno.2025.06.022. Epub 2025 Jul 17. Gynecol Oncol. 2025. PMID: 40680327 Review.
Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy.
Winterhoff BJN, Girnius N, Liu M, Kang J, Shetty M, Martinez-Gakidis MA, Xu W, Thomas M, Lahmadi L, Henstridge AZ, Baldominos P, Talukdaer S, Chang Z, Mattson J, Gruner M, Mullany SA, Argenta P, Konecny GE, Slamon DJ, Drapkin R, Nelson AC, Starr TK, Brugge JS. Winterhoff BJN, et al. Among authors: brugge js. bioRxiv [Preprint]. 2025 Jun 25:2025.06.24.661404. doi: 10.1101/2025.06.24.661404. bioRxiv. 2025. PMID: 40667229 Free PMC article. Preprint.
Author Correction: Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer.
Li CM, Cordes A, Oliphant MUJ, Quinn SA, Thomas M, Selfors LM, Silvestri F, Girnius N, Rinaldi G, Zoeller JJ, Shapiro H, Tsiobikas C, Gupta KP, Pathania S, Regev A, Kadoch C, Muthuswamy SK, Brugge JS. Li CM, et al. Among authors: brugge js. Nat Genet. 2024 Dec;56(12):2842. doi: 10.1038/s41588-024-02034-9. Nat Genet. 2024. PMID: 39567749 No abstract available.
Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations.
Williams MJ, Oliphant MUJ, Au V, Liu C, Baril C, O'Flanagan C, Lai D, Beatty S, Van Vliet M, Yiu JC, O'Connor L, Goh WL, Pollaci A, Weiner AC, Grewal D, McPherson A, Norton K, Moore M, Prabhakar V, Agarwal S, Garber JE, Dillon DA, Shah SP, Brugge JS, Aparicio S. Williams MJ, et al. Among authors: brugge js. Nat Genet. 2024 Dec;56(12):2753-2762. doi: 10.1038/s41588-024-01988-0. Epub 2024 Nov 20. Nat Genet. 2024. PMID: 39567747 Free PMC article.
Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer.
Li CM, Cordes A, Oliphant MUJ, Quinn SA, Thomas M, Selfors LM, Silvestri F, Girnius N, Rinaldi G, Zoeller JJ, Shapiro H, Tsiobikas C, Gupta KP, Pathania S, Regev A, Kadoch C, Muthuswamy SK, Brugge JS. Li CM, et al. Among authors: brugge js. Nat Genet. 2024 Dec;56(12):2763-2775. doi: 10.1038/s41588-024-01958-6. Epub 2024 Nov 11. Nat Genet. 2024. PMID: 39528827
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen H, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI. Corcoran RB, et al. Among authors: brugge js. Clin Cancer Res. 2024 May 1;30(9):1739-1749. doi: 10.1158/1078-0432.CCR-23-3135. Clin Cancer Res. 2024. PMID: 38456660 Free PMC article. Clinical Trial.
Single-cell transcriptomics identifies a WNT7A-FZD5 signaling axis that maintains fallopian tube stem cells in patient-derived organoids.
Alsaadi A, Artibani M, Hu Z, Wietek N, Morotti M, Gonzalez LS, Alazzam M, Jiang J, Abdul B, Soleymani Majd H, Blazer LL, Adams J, Silvestri F, Sidhu SS, Brugge JS, Ahmed AA. Alsaadi A, et al. Among authors: brugge js. Cell Rep. 2023 Nov 28;42(11):113354. doi: 10.1016/j.celrep.2023.113354. Epub 2023 Nov 1. Cell Rep. 2023. PMID: 37917586 Free article.
146 results